Hyperinsulinemic Therapy in Sepsis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2013 by McGill University Health Center.
Recruitment status was  Active, not recruiting
Information provided by (Responsible Party):
peter metrakos, McGill University Health Center
ClinicalTrials.gov Identifier:
First received: November 18, 2010
Last updated: October 24, 2013
Last verified: October 2013

Insulin regulates blood sugar and acts to suppress inflammation. Hyperinsulinemic Therapy is a protocol for Insulin administration that involves the administration of a calculated higher dose of insulin into the blood stream. This therapy is called dextrose/insulin clamp. It has been shown to be safe and successful in maintaining normal glucose levels.

The objective of the study is to assess if the clamp can achieve a steady and normal blood glucose level in patients admitted to the intensive care unit with sepsis. Furthermore, if the higher insulin dose would lead to a drop in the inflammatory response seen in septic patients.

Condition Intervention
Drug: Insulin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Hyperinsulinemic Therapy in Sepsis

Resource links provided by NLM:

Further study details as provided by McGill University Health Center:

Primary Outcome Measures:
  • Glucose Control [ Time Frame: During ICU stay (average one week) ] [ Designated as safety issue: Yes ]
    Measures glucose control using the hyperinsulinemic/normoglycemic clamp in patients with septic shock

Secondary Outcome Measures:
  • Inflammatory cytokines and biochemical hormonal response [ Time Frame: At randomization then at 6,24, 120 hours ] [ Designated as safety issue: No ]
    Measurement of specific cytokines and hormonal responses to hyperinsulinemic therapy in patients with septic shock

Estimated Enrollment: 15
Study Start Date: November 2010
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tight Glucose Control Hyperinsulinemic Group Drug: Insulin
Intravenous Hyperinsulinemic therapy
Experimental: Non-Tight Glucose Control Hyperinsulinemic Group Drug: Insulin
Intravenous Hyperinsulinemic therapy
Active Comparator: Standard Insulin Protocol Group Drug: Insulin
Standard Intravenous Insulin Therapy


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Admission to the ICU with a diagnosis of Septic shock or Severe Sepsis.

Exclusion Criteria:

  • Age less than 18 years old.
  • Pregnancy.
  • Patients who cannot provide informed consent and there is no surrogate decision maker.
  • A delay of more than 24 hours between eligibility and randomization.
  • Patients admitted to the intensive care unit for treatment of diabetic ketoacidosis or hyperosmolar state.
  • Imminent death.
  • Patients who the treating clinicians are not committed to full supportive care. This is confirmed by a documented treatment-limitation order that exceeds a "do-not-resuscitation" order.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01244178

Canada, Quebec
Royal Victoria Hospital
Montreal, Quebec, Canada, H3A 1A1
Montreal General Hospital
Montreal, Quebec, Canada, H3G 1A4
Saudi Arabia
King Khalid Univesity Hospital
Riyadh, Saudi Arabia, 11421
Sponsors and Collaborators
peter metrakos
Principal Investigator: Peter Metrakos, FRCSC McGill University
  More Information

Responsible Party: peter metrakos, Associate Professor of Surgery and Associate Professor in Anatomy and Cell Biology McGill University, McGill University Health Center
ClinicalTrials.gov Identifier: NCT01244178     History of Changes
Other Study ID Numbers: 10-003-GEN 
Study First Received: November 18, 2010
Last Updated: October 24, 2013
Health Authority: Canada: Ethics Review Committee

Keywords provided by McGill University Health Center:

Additional relevant MeSH terms:
Pathologic Processes
Systemic Inflammatory Response Syndrome
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016